spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Cetrorelix 

 HSMN NewsFeed - 19 Aug 2022
Calyptus Pharmaceuticals Announces FDA Approval of Cetrorelix Acetate for Injection, 0.25 mg/vial
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 16 Aug 2022
Akorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 18 Dec 2009
Aeterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Dec 2009
AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 17 Aug 2009
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 6 Mar 2009
Sanofi-aventis and AEterna Zentaris Sign Agreement in the U.S.
Biopharmaceuticals Licensing Urology
 HSMN NewsFeed - 6 Mar 2009
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Licensing Urology
 HSMN NewsFeed - 12 Aug 2008
AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2008
AEterna Zentaris Announces Changes to its Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Mar 2008
Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 16 Aug 2007
AEterna Zentaris completes management team with the appointment of Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2007
AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights from Solvay for Cetrorelix in Endometriosis Indication
Biopharmaceuticals
 HSMN NewsFeed - 7 May 2007
AEterna Zentaris Bolsters Management Team with Two Key Positions Named
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Apr 2007
AEterna Zentaris Reports First Patients Treated with Cetrorelix for Phase 3 Program in BPH
Biopharmacetuicals Urology
 HSMN NewsFeed - 8 Jan 2007
AEterna Zentaris Initiates First Study of Phase 3 Program with Cetrorelix in BPH - 600 Patient Trial Conducted in the United States and Canada
Biopharmaceuticals Urology
 HSMN NewsFeed - 21 Jun 2006
AEterna Zentaris Receives Green Light from FDA to Move Forward into Phase 3 Program with Cetrorelix in BPH
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 20 Apr 2006
AEterna Zentaris Gains Market Approval for Cetrotide(R) (cetrorelix) in Japan for In Vitro Fertilization
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jan 2006
AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights for Cetrorelix in Benign Prostate Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 25 Jan 2006
AEterna Zentaris appoints former Abbott Vice President to its Board of Directors
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
Cetrorelix
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.